Discover and read the best of Twitter Threads about #Yervoy
Most recents (2)
1/ “Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy.” $PVCT thoughts: there’s no free lunch. A THREAD.
2/ 20Mar23: Endpoints: “BioNTech to pay $200M upfront in CTLA-4 antibody development, commercialization deal.” endpts.com/biontech-to-pa….
3/ The CTLA-4 asset BioNTech acquired is ONC-392. See here from #SITC21: jitc.bmj.com/content/jitc/9….
$PVCT Releases 2023 Stockholder Letter globenewswire.com/news-release/2… #rosebengal #rosebengalsodium
1/ $PVCT 2023 Shareholder Letter: (2) Design, prepare, and potentially commence a Phase 2/3 RCT of PV-10®+SOC checkpoint vs monotherapy SOC checkpoint ($MRK #keytruda, $BMY #opdivo) for 1st-line Stage III cutaneous melanoma. #rosebengal #rosebengalsodium. A THREAD.
2/ Utilizing clinical data from an ongoing, multi-cohort, Phase 1b/2 study of PV-10+checkpoint ($MRK #keytruda) for checkpoint-naïve metastatic melanoma (NCT02557321). #rosebengal #rosebengalsodium.
